Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

The New York Times looks at why hospital gowns are so unflattering. In Washington state, four agricultural workers tested ...

Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Essex LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.0% during the third quarter, according to the company in its most recent 13F filing with the ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other the Stock That Will Make You Rich in 5-10 Years. The US economy grew by 3% in the ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...